Pharmaceutical

Jazz Pharma’s Enrylaze wins European approval for AML and LBL

The European Commission has approved Enrylaze for treating acute lymphoblastic leukaemia and lymphoblastic lymphoma.

Sep 23, 2023 - 20:00
Jazz Pharma’s Enrylaze wins European approval for AML and LBL
The European Commission has approved Enrylaze for treating acute lymphoblastic leukaemia and lymphoblastic lymphoma.
Read the original article

Tags:

Previous Article

FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408

Next Article

Over half of world’s population not covered by essential healthcare services

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

After early-stage breast cancer, interrupting endocrine therapy to become pregnant didn’t raise risk of recurrence

After early-stage breast cancer, interrupting endocrine...

May 3, 2023

STAT+: Cracking an intriguing secret of centenarians: Why so few are ravaged by Alzheimer’s disease

STAT+: Cracking an intriguing secret of centenarians: W...

May 9, 2023

HCA Healthcare gets grant for wrist brace with advantag...

Apr 5, 2024